21st World Congress on Neurology and Therapeutics

March 15-17, 2018 | London, UK

Skeletal myotubes and muscles expressing human ALS-causing genes trigger motoneuron neurodegeneration through the release of a toxic factor(s)

Pablo Martinez Contreras¹, María Florencia Tevy², Enrique Jaimovich³ and Brigitte van Zundert¹ ¹Universidad Andres Bello, Chile ²Universidad Mayor, Chile ³Universidad de Chile. Chile

Despite that ALS is considered a central nervous system disease, recent studies show that restricted expression of hSOD1^{G93A} in mouse muscles induces motoneuron degeneration and ALS symptomatology. To gain insights into the mechanisms underlying motoneuron neurodegeneration, we established an *in vitro* culture model system using rodent hSOD1^{G93A} myotubes and wild-type motoneurons. Muscle conditional media (MCM) was prepared from cultured primary myotubes from neonatal mice expressing human SOD1^{G93A} or C9ORF72 genes. MCM-mSOD1^{WT} and non-transgenic C9ORF72 were used as controls. Wild-type primary rat ventral spinal cord cultures (VSCN) (8-10% motoneurons) at 4 DIV were incubated with MCMs. For each sample we tested motoneuron survival (SMI32/MAP2 immunostaining), ROS production (measured with DCF probe) and c-Abl phosphorylation. MCM-hSOD1^{G93A} and C9ORF72 robustly reduced motoneuron survival (40%) in 7 DIV VSCN cultures. Strong ROS production and c-Abl phosphorylation were observed 30 min after MCM-hSOD1G93A application. Further, we used Drosophila models with muscle-restricted ALS-causing genes to explore whether similar effects could be translated in vivo. Using the fly GAL4/UAS system, we expressed ALS-causing genes (hSOD1^{G85R}, hSOD1^{A4V}, hTDP43 and C9ORF72 in muscles of Drosophila reduced their climbing ability. Altogether our data provide evidence that skeletal muscle cells expressing ALScausing genes lead to motoneuron pathology and neurodegeneration through a non autonomous mechanism. We hypothesize the release of unknown toxic factor (s), as a common neurodegeneration pathway.

Biography

Pablo Martinez Contreras is a PhD candidate from Universidad Andrés Bello, with part of his thesis work performed at Massachussets Institute of Technology. In recent years, he has contributed to understanding the non-autonomous cellular mechanisms that trigger motor neuron death in ALS in both *in vitro* and in vivo models. His latest research explores the identification of toxic factors released from skeletal muscle and astrocytes as a possible therapeutic target.

martinezc.pabloa@gmail.com

Notes: